Trial Profile
A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs TCD 717 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors TCD Pharma
- 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 31 May 2012 Planned number of patients changed from 30 to 28 as reported by ClinicalTrials.gov.
- 16 Feb 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.